Molecular docking studies and biological activities of benzenesulfonamide-based thiourea and thiazolidinone derivatives targeting cholinesterases, α-glucosidase, and α-amylase enzymes

Alzheimer's disease (AD) and diabetes mellitus (DM) are related to abnormal changes in enzyme activity. While acetylcholinesterase (AChE) butyrylcholinesterase (BChE) the primary targets treatment of (AD), α-glucosidase (α-Gly) α-amylase (α-Amy) enzymes known for (DM). Here, benzenesulfonamide-based thiourea thiazolidinone derivatives such as AChE, BChE, α-Gly, α-Amy inhibitors were reported. The results revealed that compounds 1d 2c showed promising AChE BChE inhibition effects. Compound 2a was most potent inhibitor against α-glycosidase α-amylase, respectively. Molecular docking studies indicated lead compounds' binding energy values molecular interactions better than tacrine acarbose. bioactive may be considered leads further studies.